墨西哥患者的风险分层和血脂评估,REMECAR中血脂和心血管分析的证据。墨西哥心血管疾病登记处(REMECAR组)

IF 1.4 Q3 PERIPHERAL VASCULAR DISEASE Atherosclerosis plus Pub Date : 2022-12-01 DOI:10.1016/j.athplu.2022.08.002
Manuel Odín De los Ríos-Ibarra , José Luis Leiva-Pons , Humberto Rodríguez-Reyes , Marco Antonio Alcocer-Gamba , Jorge Cortés-Lawrenz , Frida María Vizcaíno-Rios , Jaime Barragán-Luna , Julio Iván Farjat-Ruiz , Luis R. Virgen-Carrillo , Francisco Padilla-Padilla , Abel Pavia-López , Enrique C. Morales-Villegas , Natalie C. Ward , Leslie Marisol Lugo-Gavidia
{"title":"墨西哥患者的风险分层和血脂评估,REMECAR中血脂和心血管分析的证据。墨西哥心血管疾病登记处(REMECAR组)","authors":"Manuel Odín De los Ríos-Ibarra ,&nbsp;José Luis Leiva-Pons ,&nbsp;Humberto Rodríguez-Reyes ,&nbsp;Marco Antonio Alcocer-Gamba ,&nbsp;Jorge Cortés-Lawrenz ,&nbsp;Frida María Vizcaíno-Rios ,&nbsp;Jaime Barragán-Luna ,&nbsp;Julio Iván Farjat-Ruiz ,&nbsp;Luis R. Virgen-Carrillo ,&nbsp;Francisco Padilla-Padilla ,&nbsp;Abel Pavia-López ,&nbsp;Enrique C. Morales-Villegas ,&nbsp;Natalie C. Ward ,&nbsp;Leslie Marisol Lugo-Gavidia","doi":"10.1016/j.athplu.2022.08.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><p>Dyslipidaemia is a significant risk factor for cardiovascular disease in the Mexican population. This analysis aimed to describe the baseline LDL-c levels of patients presenting to cardiovascular clinics and evaluate the proportion who achieved their risk-based LDL-c goals as recommended by 2021 ESC prevention guidelines.</p></div><div><h3>Methods</h3><p>The REMECAR registry is an observational study of patients attending a specialized cardiovascular clinic for their first visit. The cardiovascular risk was retrospectively determined using the 2021 ESC guideline stratification and the SCORE2 and SCORE-OP.</p></div><div><h3>Results</h3><p>A total of 5443 patients were included in the analysis. Within this population, 55.96% presented as very high, 39.98% as high and 4.06% as moderate to low risk. 63% of the participants were not on any lipid-lowering treatment at entry, while 12.4% were receiving high-intensity statin therapy. Patients presenting with established atherosclerotic cardiovascular disease had a mean LDL-c of 90.9 ± 40.7 mg/dL. Of these, 14.1% were achieving LDL-c levels of 70–55 mg/dL and 19.3% were achieving LDL-c levels &lt;55 mg/dL. In diabetic patients at very high risk, only 25.7% achieved their LDL-c goal. Finally, in patients without another risk factor and very high-risk evaluated by SCORE2 &amp; SCORE-OP, only 14% of patients achieved their LDL-c goals.</p></div><div><h3>Conclusions</h3><p>An important number of patients were not receiving any lipid-lowering therapy. Furthermore, in those who were, a significant portion did not achieve LDL-c recommended thresholds. Our results underline the urgent need to improve the prescription and optimization of lipid-lowering therapy as the current management appears to be insufficient for achieving optimal recommended goals. Identifying key barriers in lipid management is fundamental to establishing better strategies and health system policies to reduce cardiovascular risk.</p></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/2c/main.PMC9833238.pdf","citationCount":"0","resultStr":"{\"title\":\"Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group)\",\"authors\":\"Manuel Odín De los Ríos-Ibarra ,&nbsp;José Luis Leiva-Pons ,&nbsp;Humberto Rodríguez-Reyes ,&nbsp;Marco Antonio Alcocer-Gamba ,&nbsp;Jorge Cortés-Lawrenz ,&nbsp;Frida María Vizcaíno-Rios ,&nbsp;Jaime Barragán-Luna ,&nbsp;Julio Iván Farjat-Ruiz ,&nbsp;Luis R. Virgen-Carrillo ,&nbsp;Francisco Padilla-Padilla ,&nbsp;Abel Pavia-López ,&nbsp;Enrique C. Morales-Villegas ,&nbsp;Natalie C. Ward ,&nbsp;Leslie Marisol Lugo-Gavidia\",\"doi\":\"10.1016/j.athplu.2022.08.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and aims</h3><p>Dyslipidaemia is a significant risk factor for cardiovascular disease in the Mexican population. This analysis aimed to describe the baseline LDL-c levels of patients presenting to cardiovascular clinics and evaluate the proportion who achieved their risk-based LDL-c goals as recommended by 2021 ESC prevention guidelines.</p></div><div><h3>Methods</h3><p>The REMECAR registry is an observational study of patients attending a specialized cardiovascular clinic for their first visit. The cardiovascular risk was retrospectively determined using the 2021 ESC guideline stratification and the SCORE2 and SCORE-OP.</p></div><div><h3>Results</h3><p>A total of 5443 patients were included in the analysis. Within this population, 55.96% presented as very high, 39.98% as high and 4.06% as moderate to low risk. 63% of the participants were not on any lipid-lowering treatment at entry, while 12.4% were receiving high-intensity statin therapy. Patients presenting with established atherosclerotic cardiovascular disease had a mean LDL-c of 90.9 ± 40.7 mg/dL. Of these, 14.1% were achieving LDL-c levels of 70–55 mg/dL and 19.3% were achieving LDL-c levels &lt;55 mg/dL. In diabetic patients at very high risk, only 25.7% achieved their LDL-c goal. Finally, in patients without another risk factor and very high-risk evaluated by SCORE2 &amp; SCORE-OP, only 14% of patients achieved their LDL-c goals.</p></div><div><h3>Conclusions</h3><p>An important number of patients were not receiving any lipid-lowering therapy. Furthermore, in those who were, a significant portion did not achieve LDL-c recommended thresholds. Our results underline the urgent need to improve the prescription and optimization of lipid-lowering therapy as the current management appears to be insufficient for achieving optimal recommended goals. Identifying key barriers in lipid management is fundamental to establishing better strategies and health system policies to reduce cardiovascular risk.</p></div>\",\"PeriodicalId\":72324,\"journal\":{\"name\":\"Atherosclerosis plus\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/2c/main.PMC9833238.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Atherosclerosis plus\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667089522000463\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667089522000463","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的在墨西哥人群中,血脂异常是心血管疾病的重要危险因素。该分析旨在描述到心血管诊所就诊的患者的基线LDL-c水平,并评估达到2021年ESC预防指南推荐的基于风险的LDL-c目标的比例。方法REMECAR登记是一项观察性研究,研究对象是首次到心血管专科诊所就诊的患者。采用2021年ESC指南分层和SCORE2和SCORE-OP回顾性确定心血管风险。结果共纳入5443例患者。在该人群中,55.96%为极高风险,39.98%为高风险,4.06%为中至低风险。63%的参与者在入组时没有接受任何降脂治疗,而12.4%的参与者接受了高强度他汀类药物治疗。确诊为动脉粥样硬化性心血管疾病的患者的平均LDL-c为90.9±40.7 mg/dL。其中,14.1%的患者LDL-c水平达到70-55 mg/dL, 19.3%的患者LDL-c水平达到55 mg/dL。在高危糖尿病患者中,只有25.7%达到了LDL-c目标。最后,在没有其他危险因素且经SCORE2评估为高危的患者中;SCORE-OP,只有14%的患者达到了他们的LDL-c目标。结论有相当一部分患者未接受任何降脂治疗。此外,在那些没有达到LDL-c推荐阈值的人中,有很大一部分没有达到推荐阈值。我们的结果强调迫切需要改进处方和优化降脂治疗,因为目前的管理似乎不足以实现最佳推荐目标。确定脂质管理中的关键障碍对于制定更好的战略和卫生系统政策以降低心血管风险至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group)

Background and aims

Dyslipidaemia is a significant risk factor for cardiovascular disease in the Mexican population. This analysis aimed to describe the baseline LDL-c levels of patients presenting to cardiovascular clinics and evaluate the proportion who achieved their risk-based LDL-c goals as recommended by 2021 ESC prevention guidelines.

Methods

The REMECAR registry is an observational study of patients attending a specialized cardiovascular clinic for their first visit. The cardiovascular risk was retrospectively determined using the 2021 ESC guideline stratification and the SCORE2 and SCORE-OP.

Results

A total of 5443 patients were included in the analysis. Within this population, 55.96% presented as very high, 39.98% as high and 4.06% as moderate to low risk. 63% of the participants were not on any lipid-lowering treatment at entry, while 12.4% were receiving high-intensity statin therapy. Patients presenting with established atherosclerotic cardiovascular disease had a mean LDL-c of 90.9 ± 40.7 mg/dL. Of these, 14.1% were achieving LDL-c levels of 70–55 mg/dL and 19.3% were achieving LDL-c levels <55 mg/dL. In diabetic patients at very high risk, only 25.7% achieved their LDL-c goal. Finally, in patients without another risk factor and very high-risk evaluated by SCORE2 & SCORE-OP, only 14% of patients achieved their LDL-c goals.

Conclusions

An important number of patients were not receiving any lipid-lowering therapy. Furthermore, in those who were, a significant portion did not achieve LDL-c recommended thresholds. Our results underline the urgent need to improve the prescription and optimization of lipid-lowering therapy as the current management appears to be insufficient for achieving optimal recommended goals. Identifying key barriers in lipid management is fundamental to establishing better strategies and health system policies to reduce cardiovascular risk.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Atherosclerosis plus
Atherosclerosis plus Cardiology and Cardiovascular Medicine
CiteScore
2.60
自引率
0.00%
发文量
0
审稿时长
66 days
期刊最新文献
Adherence to the Healthy Nordic Food Index is associated with reduced plasma levels of inflammatory markers in patients with heterozygous familial hypercholesterolemia A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: Protocol for the EAS Lipid Registry of Africa (LIPRA) Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action? Coronary artery calcification score and 19 biomarkers on cardiovascular events; a 10-year follow-up DanRisk substudy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1